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Title: Characterizing indeterminate (Likert-scored 3/5) peripheral zone 
prostate lesions with PSA density, PI-RADS scoring and qualitative 
descriptors on multi-parametric MRI. 
 
Manuscript type: Original Research 
 
ABSTRACT: 
Objectives: To determine whether indeterminate (Likert-score 3/5) peripheral 
zone (PZ) multi-parametric MRI (mpMRI) studies are classifiable by Prostate-
Specific Antigen (PSA), PSA density (PSAD), PI-RADS_v2 rescoring and 
morphological MRI features.  
 
Methods:  
Men with maximum Likert-score 3/5 within their PZ were retrospectively 
selected from 330 men who prospectively underwent prostate mpMRI (3T) 
without an endorectal coil, followed by twenty-zone trans-perineal template 
prostate mapping biopsies ± focal lesion-targeted biopsy. PSAD was 
calculated using pre-biopsy PSA and MRI-derived volume. Two readers A and 
B independently assessed included men with both subjective Likert-score and 
PI-RADS_v2. Both readers then classified mpMRI morphological features in 
consensus. Men were divided into two groups: significant cancer (≥Gleason 
3+4) or insignificant cancer (≤Gleason 3+3)/no cancer. Comparisons between 
groups were made separately for PSA&PSAD using Mann-Whitney test and 
morphological descriptors with Fisher’s exact test. PI-RADS_v2 and 
Revised Manuscript - Clean
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subjective Likert assessment were descriptively compared and percentage 
inter-reader agreement calculated. 
 
Results: 
76 men were eligible for PSA&PSAD analyses, 71 for PI-RADS scoring, and 
67 for morphological assessment (excluding significant image artefacts). 
Unlike PSA (p=0.915), PSAD was statistically different (p=0.004) between the 
significant 0.19 ng/ml2 (IQR: 0.13-0.29) and non-significant/no cancer 0.13 
ng/ml2 (IQR: 0.10-0.17) groups. Presence of mpMRI morphological features 
wasn’t significantly different between groups. Subjective Likert assessment 
discriminated patients with significant cancer better than PI-RADS_v2. Inter-
reader percentage agreement was 83% for subjective Likert-scoring and 56% 
for PI-RADS_v2. 
 
Conclusion:  
PSAD may categorize presence of significant cancer in patients with Likert-
scored 3/5 PZ mpMRI findings. 
 
Advances in knowledge: PSAD may be used in indeterminate PZ mpMRI to 
guide decisions between biopsy versus monitoring. 
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INTRODUCTION: 
Multi-parametric MRI (mpMRI) has the potential to be the modality of choice 
for ruling out clinically significant prostate cancer with reported negative 
predictive values as high as 89% (83-94%) (1, 2). However, prostate mpMRI 
is scored as indeterminate (Likert-score 3/5) in almost 1/3rd of cases (163 of 
576 patients enrolled in the recent multi-centre prospective PROMIS study) 
where the radiologist is unable to confirm or refute the presence of clinically 
significant cancer. 
  
Two scoring systems are commonly used to evaluate the likelihood of 
prostate cancer on mpMRI (3-6). First, the Prostate Imaging Reporting And 
Data System version 2 (PI-RADS_v2) which uses explicit criteria based on a 
zonal mpMRI dominant sequence (e.g diffusion-weighted imaging in the 
peripheral zone and T2-weighted imaging in the transition zone) to rate the 
suspicion of prostate cancer on a five-point scale (7) and second, a subjective 
five-point Likert assessment (8), based on each mpMRI sequence equally 
(unlike the use of dominant sequence in PIRADS_v2) and adapted to the 
radiologist’s experience for overall impression. Both 5-point scales define the 
likelihood for the presence of prostate cancer, as follows 1: highly unlikely, 2: 
unlikely, 3: equivocal, 4: likely, 5: highly likely). Subjective Likert scoring has 
recently been prospectively validated in the multi-centre, multi-reader 
PROMIS trial (1). PI-RADS_v2 remains more widely accepted where 
prospectively scored cohorts have also been reported (9) but studies with 
head-to-head comparisons of PI-RADS_v2 and Likert-assessment as scoring 
systems are lacking. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
BJ
R U
NC
OR
RE
CT
ED
 PR
OO
FS
 5 
  
Indeterminate mpMRI poses both a management dilemma and potential 
unnecessary increase in healthcare cost. If all patients within this group were 
biopsied, a majority of men without significant disease would be exposed to 
potentially unnecessary risks of haemorrhage and urinary tract infections, 
which can lead to hospitalization (10) further increasing healthcare costs; 
conversely, if all men were not biopsied then a significant proportion of men 
would have significant cancer missed.  This cohort of patients has been 
scarcely studied as an independent group (11, 12) since most attention so far, 
has been focused on both extremes of the scale (13-16). Decreasing the 
number of equivocal mpMRI scans remains an unmet clinical challenge and 
represents a determinant factor for widespread global adoption of mpMRI. 
 
The prevalence of prostate cancer is higher in the peripheral zone than the 
transition zone and zone-specific molecular and imaging phenotypes exist, 
prompting separate zonal assessment (17-19).  
  
The aim of this work was to determine whether indeterminate (Likert-score 
3/5) peripheral zone (PZ) multi-parametric MRI (mpMRI) studies can be 
categorized into significant/insignificant cancer by Prostate-Specific Antigen 
(PSA), PSA density (PSAD), PI-RADS_v2 rescoring and morphological MRI 
features. 
 
MATERIALS AND METHODS 
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Local institutional review board waived the requirement for individual consent 
for this single-center retrospective analysis of prospectively enrolled patients 
from a previous study cohort (20) - Research Ethics Committee reference 
11/LO/1657.  
  
Patients 
330 men (median age: 63 years, interquartile range, IQR [42-83]; median 
PSA: 7.4 ng/ml, IQR [0.7-58.05]), with prior negative/non-significant prostate 
disease on TRUS biopsies, but in whom a clinical suspicion of prostate cancer 
remained (elevated PSA or PSA kinetics, abnormal digital rectal examination, 
etc) were consecutively enrolled from January 2012-2014 (20). They all 
underwent prostate mpMRI without an endorectal coil at 3T (unless 
contraindicated). A radiologist (Reader A) with 10 years of experience in 
prostate imaging, blinded to histopathological results, prospectively reported 
mpMRI findings and scored the likelihood of significant cancer on a subjective 
5-point Likert scale. All patients underwent 20-zone trans-perineal template 
prostate mapping (TPM) biopsies (21). In addition, when a focal lesion was 
identified on mpMRI, its location was mapped on a prostate gland 
representative diagram and its biopsy template grid co-ordinates noted (21). 
MR-guided targeted biopsies were performed by experienced urologists (≥ 10 
years of experience), aware of the radiologist’s report, as described within the 
previous study protocol (20).  
 
Men with complete 3T mpMRI datasets, full template biopsy ± targeted biopsy 
and maximum Likert-scored 3/5 PZ were eligible for inclusion. 107/330 
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patients fulfilled these criteria. Patients with a concurrent Likert-score 3/5 in 
the transition zone (TZ) subsequently identified as clinically significant tumour 
were excluded (n=6), men with a lack of complete gland sampling/ inadequate 
sampling density were excluded (n=20), and five men who underwent 1.5T 
scans were excluded. The final cohort comprised of 76/107 PZ Likert-scored 
3/5 mpMRI studies for analysis. Figure 1 summarizes the patient selection. 
 
MpMRI Protocol 
The 3T mpMRI protocol for included men (Table 1) has been previously 
described (22). All studies were performed with the same protocol on a single 
3T scanner (Achieva®, Philips Healthcare, Netherlands) using a 32-channel 
pelvic-phased array coil. Briefly, sequences included axial turbo spin echo 
and coronal T2W; axial DWI using a high b-value at 2000s/mm2; axial ADC 
map generated by diffusion gradients b0, b150, b500, and b1000 (s/mm2) and 
axial T1W dynamic–contrast enhanced sequences before and after 
intravenous administration of at least 0.1 mmol/kg gadolinium meglumine 
contrast agent (Dotarem®, Guerbet, France) at a rate of 3ml/s via power 
injector, followed by 20ml saline bolus at the same rate with a temporal 
resolution of 15 seconds.  
 
Cancer Significance 
Histology results were reported by a uro-pathologist with 12 years of 
experience. Recognizing that there still is an ongoing debate on what 
constitutes clinically significant prostate cancer, for the purposes of this study, 
the presence of any Gleason 7 pattern or higher (≥ 3+4), anywhere within the 
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PZ was considered as clinically significant (23). The maximum cancer core 
length (MCCL) was measured and categorized as <6mm or ≥6mm.  
 
Correlation of Trans-perineal Template Mapping Biopsies and MpMRI 
For mpMRI to histopathology matching, Likert-scores 3/5 at the apex and 
base were considered positive for significant cancer if the corresponding 
Barzell zone was positive on biopsy. Likert-scores 3/5 at the mid-gland level 
were considered positive if the corresponding apical or basal Barzell zone 
was positive on biopsy. A schema for correspondence of Barzell zones on 
TPM (21) and prostate mpMRI region is illustrated in Figure 2.  
 
Serum PSA and PSA Density 
PSA prior to entry of patients into the previous study (14) was recorded. To 
calculate PSA density, the prostate volume was measured on the mpMRI 
study. The maximum antero-posterior and latero-lateral diameters of the 
prostate were manually measured by Reader A on axial T2W slices while its 
cranio-caudal diameter was measured on coronal T2W slices as shown in 
Figure 3. Assuming an ellipsoid shape of the prostate, its volume was 
calculated by Reader A as the product of the three diameters and π/6 (24). 
PSAD was calculated by the quotient of serum PSA over the gland volume.  
 
Likert to PI-RADS Scoring  
Reader A, who reported the mpMRI of the prostate as Likert-score 3/5 in the 
previous study (22), rescored them with PI-RADS_v2 criteria (8). A second 
radiologist, Reader B (4 years of experience in reading prostate mpMRI) 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
BJ
R U
NC
OR
RE
CT
ED
 PR
OO
FS
 9 
independently rescored the scans, using first Likert scoring, then at different 
time points with PI-RADS_v2. Both readers were blinded to histopathological 
reports, unaware of each other’s scores.  
 
Peripheral Zone MpMRI Morphology 
As Likert-score 3/5 exhibit varied appearances on mpMRI, the 
presence/absence of the morphological descriptors (described below and in 
Figures 4A-4C) of PZ signal changes on all combined sequences were 
considered by Readers A and B in consensus (as no pre-defined 
morphological validated classification scheme has yet been reported for 
Likert-score 3/5 cohorts). This was assessed only after the subjective Likert 
and PI-RADS_v2 scores of both readers had been locked. 
 
i) “discrete focal” – single or multiple focal changes occupying <50% 
of PZ,  
ii) “diffuse homogeneous” – uninterrupted signal changes occupying 
>50% of PZ, and without focal intensity variation,  
iii) “diffuse inhomogeneous” – signal changes occupying >50% of PZ 
interrupted by focal intensity variation or stranded changes 
 
Statistical Analyses 
The Mann-Whitney tests were used to compare each PSA and PSAD 
between clinically significant and non-significant/no cancer groups. From a 
receiver-operating characteristic (ROC) curve, sensitivity and specificity of 
various PSAD thresholds were obtained and the highest Youden’s J index 
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was determined to identify PSAD threshold for significant cancer in our cohort 
(25). Proportions of up-scored, down-scored and unchanged Likert and PI-
RADS scores per reader were descriptively compared. Inter-reader 
percentage agreement for Likert and PI-RADS were calculated. The Kappa 
agreement coefficient, κ, between both readers was also computed for PI-
RADS (κ < 0.4: fair, 0.4< κ <0.8: moderate, κ> 0.8: strong agreement). PZ 
morphological descriptors were compared between significant and 
insignificant cancer groups with Fisher’s exact test. Statistical significance 
was set at p<0.05. GraphPad Prism statististical software (version 6, 
GraphPad Software, San Diego, CA) was used. 
 
RESULTS 
Of 76 men (median age 61 years IQR 57-66; median PSA 7.2 ng/ml IQR 
4.9-10.3; median gland volume 52 cc IQR 33-63), 21 (27%) had a clinically 
significant cancer at biopsy, 31 (41%) harbored low grade (Gleason 3+3) 
disease, and 24 (32%) had no cancer (including high-grade prostate intra-
epithelial neoplasm, atypical acini, inflammation, atrophy, and/or benign 
cores). 
 
Serum PSA and PSA Density 
Median PSA and PSAD were 7.17 ng/ml (IQR: 5.55-8.69) and 0.19 ng/ml2 
(IQR: 0.13-0.29) in the significant cancer group while in the non-significant/no 
cancer group, these were 7.20 ng/ml (IQR: 4.31-10.7) and 0.13 ng/ml2 (IQR: 
0.10-0.17) respectively. PSAD was significantly higher in the significant 
cancer group (p=0.004) as represented in Figure 5; PSA was not significantly 
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different between the two groups (p=0.915). A PSAD threshold of >0.17 
ng/ml2 [sensitivity: 67% (95CI: 43-85%), specificity: 75% (95CI: 61-85%), 
NPV: 85% (95%CI: 72-94%] for significant cancer was identified in our cohort 
with the Youden’s index. To maximize sensitivity, the use of >0.10 ng/ml2 as 
PSAD threshold would yield 90% sensitivity (95CI: 70-99%), a reduced 
specificity of 36% (95CI: 23-50%)] but NPV would increase to 89% (95CI: 67-
99%).  
 
Likert to PI-RADS Rescoring 
Of 76 patients, five had extensive post-biopsy artefact, leaving 71 patients 
eligible for PZ PI-RADS scoring. Among them, four had non-diagnostic quality 
DWI, due to air in the rectum, and PI-RADS ‘Assessment without adequate 
DWI’ was applied (8). 
 
The set of 71 patients all scored as Likert 3 by Reader A comprised of 
eighteen (18/71, 25%) clinically significant cancer at biopsy. Reader B scored 
59/71 patients as Likert 3, of whom fifteen (15/59, 25%) had clinically 
significant cancer; four were scored Likert 2 and none had clinically significant 
cancer; eight were scored Likert 4, three of which had clinically significant 
cancer (3/8, 38%) where two had Gleason 3+4 pattern and MCCL<6mm, one 
man had Gleason 4+3, MCCL≥6mm.  
 
On PI-RADS_v2 rescoring, Readers A and B down-scored to PI-RADS≤2, 
34/71 (48%) and 34/59 (58%) patients respectively; with 27/34 (79%) and 
26/34 (76%) demonstrating non-significant/no cancer at biopsy. For reader A, 
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6/34 (18%) PI-RADS≤2 scored men had Gleason 3+4 disease, MCCL<6mm 
and 1/34 man Gleason 3+4, MCCL≥6mm. For Reader B, 7/30 (23%) PI-
RADS≤2 scored men had Gleason 3+4 pattern with MCCL<6mm, 1/34 man 
Gleason 3+4, MCCL≥6mm, and 1/34 Gleason 4+3 disease.  
 
Readers A and B up-scored to PI-RADS4 in 31/71 (44 %) and 20/59 (34%) 
patients respectively, and none to PI-RADS5; with 23/31 (74%) and 13/20 
(65%) demonstrating non-significant/no cancer at biopsy. For Reader A, 6/31 
(19%) PI-RADS4 scored men had Gleason 3+4 and MCCL<6mm, 1/31 had a 
Gleason 3+4 with MCCL≥6mm, and 1/31 had Gleason 4+3 pattern. For 
Reader B, 5/20 (25%) PI-RADS 4 scored men had Gleason 3+4 and 
MCCL<6mm, and 2/20 men had Gleason 3+4, MCCL≥6mm.  Reader B 
scored five patients PI-RADS3 (none with significant cancer) while Reader A 
scored six patients PI-RADS3 where three had clinically significant cancer 
(3/6, 50%) - two of which were Gleason 3+4, MCCL<6mm and one Gleason 
3+4, MCCL≥6mm. These results are summarized in Figure 6.  
 
The percentage agreement between Readers A and B for Likert-score 3/5 
was (59/71) 83% and (40/71) 56% for PI-RADS_v2. The latter had an inter-
reader agreement coefficient Kappa of 0.27 (95% CI 0.10-0.44). 
 
Peripheral Zone mp-MRI Morphology 
Sixty-seven men were included in this analysis after excluding non-diagnostic 
DWI studies. Results of qualitative mpMRI assessment are summarized in 
Table 2. Thirteen of 47 (28%) patients with discrete focal change [median 
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volume 0.17 cc (IQR: 0.05-0.16)] demonstrated significant cancer; and 3/10 
patients with diffuse homogeneous changes also demonstrated significant 
cancer. No patient with diffuse inhomogeneous signal changes had significant 
cancer. However, differences between groups did not reach statistical 
significance (p=0.21 to 1.00). 
 
DISCUSSION 
This paper assessed whether serum PSA & PSAD, PI-RADS_v2 rescoring 
and morphological features of Likert-scored 3/5 PZ signal changes could help 
identify patients harbouring significant cancer.  
 
Firstly, we found serum PSA level by itself, was not able to identify patients 
with significant cancer. Yet, when combined with gland volume assessment, 
PSAD was the best predictor of patients with significant cancer. Rais-Bahrami 
et al reported that PSAD coupled to the number of MR suspicious lesions on 
bi-parametric MRI (T2W and DWI) improve categorization of Gleason score ≥7 
upon TRUS or MR/US fusion biopsies (26). Recently, the use of PSA density 
with mpMRI has gained further interest in improving mpMRI accuracy (27-29). 
Our study complements this work, and provides evidence that PSAD can 
specifically address the problem of indeterminate mpMRI studies.  
   
Furthermore, we reported two thresholds of PSAD for classification of patients 
with Likert-score 3/5. Various PSAD thresholds have been previously 
proposed to select patients with significant disease (27, 28, 30-33). Epstein et 
al found >0.15ng/ml2 to be associated with significant disease upon 
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prostatectomy with a 66% NPV (21). The National Comprehensive Cancer 
Network (NCCN) has adopted this value (34) while the Prostate Cancer 
Research International Active Surveillance (PRIAS) program has adopted 
>0.2ng/ml2 (33) as predictors of significant disease. In our study, Youden’s 
cut-off of PSAD>0.17 ng/ml2 in determining the presence of significant cancer 
offers a 75% specificity (95CI: 61-85%) and 85% NPV (95%CI: 72-94%). This 
would provide a prudent approach to management by accepting a higher 
number of patients to be biopsied to minimize the chances of missing patients 
with significant tumour. Were this threshold applied to our cohort of 76 
patients, it would have correctly avoided biopsy in 40/76 (53%) and led to 7/76 
(9%) patients with cancer not being immediately diagnosed. 
 
Secondly, we found a relatively poor performance of PI-RADS_v2 as a 
classifier of Likert 3/5 patients. PI-RADS_v2 rescoring from both readers, up 
or downscored almost all patients into PI-RADS≤2 and PI-RADS4 score 
groups. However, as approximately ¾ of men up-scored to PI-RADS4 had no 
significant disease (and hence would undergo unnecessary biopsy) and 
almost ¼ of men down-scored to PI-RADS≤2 had significant cancer (and 
hence significant cancer would be missed if no biopsy was performed) we 
conclude that within our patient cohort PI-RADS scoring was not a good 
classifier of patients. Our results are not unique in highlighting some current 
deficiencies within PI-RADS_v2 reporting schema (35); Besides, Vargas et al 
have also reported that it offered limited assessment of Gleason 4+3 pattern 
of volume ≤0.5ml (36).  
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Interestingly, whilst Likert scoring demonstrated 83% inter-reader 
concordance, PI-RADS_v2 showed only 56% concordance – in line with 
Greer et al who reported an overall inter-observer concordance of 58% for PI-
RADS_v2 (37) while Renard-Penna et al reported higher concordance values 
(92%) for Likert scoring (5). While no other study has compared Likert and PI-
RADS_v2 yet, some studies have compared Likert scoring to PI-RADS_v1 (4, 
5) with Vaché et al showing a more accurate performance of Likert scores (4). 
For PI-RADS_v2, Rosenkrantz et al found expert inter-reader agreement, in 
the PZ score groups of ≥4 and ≥3 to be 0.59 and 0.53 respectively (38). 
Muller et al (39) showed an overall =0.47 for PI-RADS_v2 scoring with mixed 
reader experience. Within our study, we found a smaller  of 0.27 for PI-
RADS_v2. We do not believe this to be surprising as we specifically assessed 
a subgroup (Likert 3/5) of patients where radiological assessment is inherently 
more challenging.  
  
Finally, we investigated whether any particular pattern of PZ signal change 
could help classify patients.  We found the group of patients with ‘diffuse 
inhomogeneous’ pattern did not include any patient with significant cancer. 
However, the number of patients within our cohort was too small to confirm 
the statistical significance of this observation.  
 
The results of our study are relevant to directing clinical practice following the 
recent PROMIS study publication with Likert-scored mpMRI (1). When 3/5-
scores are classified as positive, the specificity of the mpMRI study is reduced 
(5, 40). If these scores are classified as negative, the sensitivity of the mpMRI 
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test reduces. We would advocate that the Likert 3/5 score should be treated 
as a separate indeterminate group which needs further classification with 
secondary features. Using PSAD provides a simple method to manage 
patients with indeterminate scores: men with high PSAD would undergo 
biopsy; those with low PSAD may benefit from further observation (perhaps 
PSA surveillance) as our results suggest that some of them (albeit a small 
percentage) will have significant tumour. Our results support the necessity for 
continued iteration of PI-RADS reporting schema based on ongoing research 
to improve classification, minimise subjectivity and promote inter-reader 
agreement. 
  
Our study has several limitations. Firstly, it was necessary to use a template 
biopsy based reference in our cohort as it comprised many patients without 
significant cancer/any cancer and therefore could not have a prostatectomy. 
We acknowledge the limitations of template biopsy – (which has a 95% 
detection rate for significant tumours against 100% at prostatectomy (41)) – 
nevertheless unavoidable within our cohort. Secondly, although we propose 
PSAD thresholds to aid management of Likert-score 3/5 patients, the clinical 
impact of these thresholds should be prospectively validated. Thirdly, it would 
be prudent to replicate our study in other cohorts to confirm generalizability of 
our findings, both in terms patient cohorts being imaged with mpMRI (e.g. pre-
biopsy vs delayed post-biopsy) and also different MRI scanning platforms 
(e.g. 1.5T vs 3T). 
 
CONCLUSIONS 
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MR-adjusted PSAD may help classify patients with PZ Likert-scored 3/5 on 
mpMRI who have clinically significant cancer and could be used to select 
patients for biopsy over observation. Prospective studies are further required 
to validate the use of PSA density in indeterminate mpMRI cohorts.
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TABLES 
 
Table 1 
 
Table 1: Parameters of mpMRI at 3T 
Parameter 
Repetition 
Time (ms) 
Echo Time 
(ms) 
Flip Angle 
(degree) 
Orientation 
Slice 
thickness 
(mm) 
Matrix size 
Field of 
view (mm) 
Fat 
suppression 
Time for 
scan (min) 
T2 coronal 6128 100 90 Coronal 3 300x290 180 No 05:55 
T2 axial 5407 100 90 Axial 3 300x290 180 No 05:13 
DWI b 0, 150, 500, 1000 s/mm2 2753 80 90 Axial 5 168x169 220 SPAIR 05:16 
DWI b 2000 s/mm2 2000 78 90 Axial 5 168x169 220 SPIR 03:40 
DCE 20 dynamic mode sense 5.8 28 10 Axial 3 140x162 180 SPAIR 04:14 
 
Note: 
DWI: Diffusion-weighted imaging 
DCE: Dynamic Contrast-Enhanced imaging 
SPAIR: Spectral Attenuated Inversion Recovery 
SPIR: Spectral Pre-saturation with Inversion Recovery
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Table 2 
 
Table 2: Qualitative mpMRI Assessment 
Qualitative mpMRI descriptor Significant Cancer 
Non-significant 
cancer/no cancer 
Total 
Focal lesion 13 (28%) 34 (72%) 47 (70%) 
Diffuse homogeneous  changes 3 (30%) 7 (70%) 10 (15%) 
Diffuse inhomogeneous changes 0 (0%) 10 (100%) 10 (15%) 
 
Table 2 shows the number of significant cancer and non-significant cancer/no 
cancer, in each of the qualitative mpMRI descriptor groups. 
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FIGURES 
Figure 1. Flowchart diagram illustrating the patient selection process for this 
study. 
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Figure 2.  
 
Figure 2 shows the correlation of the 20 Barzell zones from template mapping 
biopsy to the corresponding regions on mpMRI. 
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Figure 3. 
 
Figure 3 illustrates T2-weighted MRI images where the antero-posterior (Da-p) 
and latero-lateral diameters (Dl-l) of the prostate gland are measured on the 
axial plane and the cranio-caudal diameter or height (Dc-c) is measured on the 
coronal plane to calculate the volume of the prostate gland by using the 
prolate ellipse formula (Da-p x Dl-l x Dc-c x 0.52). 
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Figures 4A-4C. Illustrations of morphologic mpMRI descriptors for PZ 
scored 3/5 
 
4A. A schematic representation and example of a focal lesion (occupying 
<50% of the slice) in the PZ (axial plane) in a 70 year old man with PSA of 13 
ng/ml and PSAD of 0.14 ng/ml2. The lesion is seen at 6 o’clock, hypointense 
on T2, and enhances on DCE. Histology results were benign. 
 
 
4B. A schematic representation and example of diffuse homogeneous signal 
changes in a 51 year old man with PSA of 6 ng/ml and PSAD of 0.25 ng/ml2. 
The signal changes seen are hypointense on axial T2 and the whole PZ 
enhances uninterruptedly on axial DCE. Histology results revealed Gleason 
3+4 with MCCL <6mm on the right lateral side whereas the left PZ was 
benign. 
 
4C. A schematic illustration and example of diffuse inhomogeneous changes 
in the axial plane in a 66 year old man with PSA of 5 ng/ml and PSAD of 0.09 
ng/ml2. Areas of low T2 signal interspersed by normal high T2 signal 
intensities are observed. The low T2 signal intensities of the PZ are seen to 
enhance (on > 50% of the gland) from 1 to 5 o’clock and 7 to 8 o’clock on 
DCE. Histology results were benign. 
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Figure 5. 
 
Figure 5. Bar-charts showing the median PSA density comparison between 
the significant cancer and non-significant/no cancer groups with a statistical 
difference of p <0.01. 
 
 
 
 
 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
BJ
R U
NC
OR
RE
CT
ED
 PR
OO
FS
 29 
Figure 6. 
 
 
Figure 6. Bar-charts illustrating the results of Likert and PI-RADS scoring of 
the PZ by Readers A and B. PI-RADS segregate Likert-score 3/5 lesions 
mostly into PI-RADS ≤2 and PI-RADS 4 by both Readers A and B. The 
number of Likert-indeterminate lesions decreased from 71 to 6 (8%) by 
Reader A and 5 (7%) by Reader B with PI-RADS scoring. Readers A and B 
respectively up-scored 31/71 (44%) and 20/59 (34%) to PI-RADS 4; eight of 
31 (26%) and seven of 25 (28%) had significant cancer. They down-scored 
34/71 (48%) and 34/59 (58%) to PI-RADS ≤2; seven of 34 (24%) and eight of 
31 (26%) had significant cancer. 
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